PSA Provides Higher Cancer Prediction By Race
Increased risk may be due to West African ancestry, but this finding deserves more study
FRIDAY, Feb. 27 (HealthDay News) -- Prostate-specific antigen (PSA) has a higher prediction for prostate cancer in African American men, which may be explained by genetic West African ancestry, according to a study published online Feb. 24 in Cancer Prevention Research.
Veda N. Giri, M.D., of the Fox Chase Cancer Center in Philadelphia, and colleagues prospectively studied 646 high-risk men aged 35 to 69 whose risk factors included African American race, family history of prostate cancer, or BRCA 1/2 mutations. They performed biopsies on men with PSA values below 4.0 ng/mL and determined West African ancestry by genotyping 100 informative markers.
Among the 405 men with at least one follow-up, the researchers found that African American men with a PSA of 1.5 to 4.0 ng/mL had a higher three-year prediction for prostate cancer than European American men (hazard ratios, 1.59 and 1.32, respectively). They also found that there was a trend for increasing prediction for prostate cancer with increasing genetic West African ancestry.
"'Race-specific' PSA may need to be redefined as higher prediction for prostate cancer at any given PSA in African American men," the authors conclude. "Large-scale studies are needed to confirm if genetic West African ancestry explains these findings to make progress in personalizing prostate cancer early detection."